InflaRx (IFRX) Receivables (2017 - 2024)
InflaRx's (IFRX) quarterly Receivables came in at $96172.2 in Q3 2024, up 276.39% quarter-over-quarter from $25551.3 in Q2 2024.
InflaRx (IFRX) Receivables (2017 - 2024) Analysis & Trends
InflaRx has disclosed Receivables across 4 years of filings, most recently posting $96172.2 for Q3 2024.
- Receivables for Q3 2024 came in at $96172.2, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $96172.2 (changed N/A YoY), and the FY2018 annual result was $12323.7, up 361.66% from the prior year.
- Receivables came in at $96172.2 for Q3 2024 at InflaRx, up from $25551.3 in the prior quarter.
- In the past five years, Receivables ranged from a high of $96172.2 in Q3 2024 to a low of -$38285.6 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 96,172.18 |
| Jun 30, 2024 | 25,551.31 |
| Mar 31, 2024 | -38,285.56 |
| Sep 30, 2019 | 8,950.80 |
| Jun 30, 2019 | 10,112.75 |
| Mar 31, 2019 | 11,366.29 |
| Dec 31, 2018 | 12,323.66 |
| Dec 31, 2017 | -4,709.73 |